Etazolate

Etazolate (SQ-20,009, EHT-0202) is an anxiolytic drug which is a pyrazolopyridine derivative and has unique pharmacological properties.^[1][2][3] It acts as a positive allosteric modulator of the GABA_A receptor at the barbiturate binding site,^[4][5][6][7] as an adenosine antagonist of the A₁ and A₂ subtypes,^[8] and as a phosphodiesterase inhibitor selective for the PDE4 isoform.^[9][10][11] It is currently in clinical trials for the treatment of Alzheimer's disease.^[12]

Etazolate

Clinical data
Routes of administration	Oral
ATC code	none
Legal status
Legal status	In general: uncontrolled
Identifiers
IUPAC name Ethyl 1-ethyl-4-[2-(propan-2-ylidene)hydrazinyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate
CAS Number	51022-77-6
PubChem CID	3277
IUPHAR/BPS	7336
ChemSpider	3162
UNII	I89Y79062L
ChEBI	CHEBI:138502
ChEMBL	ChEMBL356388
CompTox Dashboard (EPA)	DTXSID4048434
Chemical and physical data
Formula	C14H19N5O2
Molar mass	289.339 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCN1C2=NC=C(C(=C2C=N1)NN=C(C)C)C(=O)OCC
InChI InChI=1S/C14H19N5O2/c1-5-19-13-10(8-16-19)12(18-17-9(3)4)11(7-15-13)14(20)21-6-2/h7-8H,5-6H2,1-4H3,(H,15,18) Key:OPQRBXUBWHDHPQ-UHFFFAOYSA-N

See also

• Cartazolate
• ICI-190,622
• Tracazolate